Excellent results of screening for subsequent breast cancers in long-term survivors of childhood Hodgkin's lymphoma-Results of a population-based study.

breast screening chest irradiation childhood cancer survivor hodgkin' lymphoma long-term follow-up subsequent breast cancer

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2023
Historique:
received: 07 02 2023
accepted: 16 03 2023
medline: 20 4 2023
pubmed: 20 4 2023
entrez: 20 04 2023
Statut: epublish

Résumé

Subsequent breast cancer (SBC) represents a major complication in childhood cancer survivors and screening for SBC in survivors after incidental irradiation of breasts is recommended. In this article, we report the results and discuss benefits of SBC screening in female pts treated for Hodgkin's lymphoma (HL) in Slovenia in a period of 45 years. Between 1966 and 2010, 117 females were treated for HL under the age of 19 in Slovenia. One hundred five of them survived for 5 years and were included in our study. They were 3-18 (med. 15) years old at diagnosis and followed for 6-52 (med. 28) years. Eighty-three percent of them had chest RT with a median dose of 30 Gy. Ninety-seven (92%) of 105 pts were regularly followed according to the international guidelines including yearly screening mammography/breast MRI in those who received chest RT. We diagnosed 10 SBCs in eight pts 14-39 (med. 24) years after diagnosis at the age of 28-52 (med. 42) years. At 40 years of follow-up, cumulative incidence of SBCs in females who got chest RT was 15.2%. Seven of eight patients (with 9 SBCs) got chest RT with 24-80 (med. 36) Gy at the age of 12 to 18 (median 17) years. Two patients in this group got bilateral SBC. One patient got invasive SBC after being treated with ChT containing high-dose of anthracyclines without chest RT at the age of 13. All eight invasive SBCs were invasive ductal cancers, HER2 receptors negative, all but one with positive hormonal receptors. Six invasive cancers were of stage T1N0, one T1N1mi, only one, diagnosed before era of screening, was of T2N1. None of 8 pts died of SBC. After introduction of regular breast screening in our female patients, who received chest RT in childhood, all SBCs were of early stage and no patients died of SBC. Survivors of pediatric HL should be informed about the risk of late sequelae of treatment for HL, including SBC. Regular follow-up with breast cancer screening and breast self-examination is of vital importance in those treated with chest RT.

Identifiants

pubmed: 37077334
doi: 10.3389/fped.2023.1161128
pmc: PMC10106574
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1161128

Informations de copyright

© 2023 Zadravec Zaletel, Cesen Mazic, Jazbec, Toplak, Kos and Štrbac.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Oncol. 2020 Sep 1;38(25):2872-2882
pubmed: 32673169
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Lancet Oncol. 2013 Dec;14(13):e621-9
pubmed: 24275135
Ann Intern Med. 2020 Sep 1;173(5):331-341
pubmed: 32628531
Dtsch Arztebl Int. 2014 Jan 6;111(1-2):3-9
pubmed: 24565270
Radiother Oncol. 2017 Aug;124(2):200-203
pubmed: 28733054
J Clin Oncol. 2003 Dec 1;21(23):4386-94
pubmed: 14645429
J Natl Cancer Inst. 2009 Jun 3;101(11):806-13
pubmed: 19470947
Ann Oncol. 2014 Apr;25(4):848-851
pubmed: 24608191
JAMA. 2009 Jan 28;301(4):404-14
pubmed: 19176442
J Clin Oncol. 2000 Feb;18(4):765-72
pubmed: 10673517
J Clin Oncol. 2016 Mar 20;34(9):910-8
pubmed: 26700127
N Engl J Med. 1996 Mar 21;334(12):745-51
pubmed: 8592547
J Clin Oncol. 2009 Aug 20;27(24):3901-7
pubmed: 19620485
Clin Cancer Res. 2007 Jan 1;13(1):46-51
pubmed: 17200337
JAMA. 2008 Jan 9;299(2):194-201
pubmed: 18182601
Br J Cancer. 2017 Jul 11;117(2):290-299
pubmed: 28632729
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
J Clin Oncol. 2002 Apr 15;20(8):2085-91
pubmed: 11956269
Ann Intern Med. 2004 Oct 19;141(8):590-7
pubmed: 15492338
J Clin Oncol. 2020 Dec 10;38(35):4194-4207
pubmed: 33078972
Nat Rev Cancer. 2014 Jan;14(1):61-70
pubmed: 24304873
Breast J. 2008 Jan-Feb;14(1):39-48
pubmed: 18186864
J Clin Oncol. 1998 Feb;16(2):536-44
pubmed: 9469338
Med Pediatr Oncol. 2000 Apr;34(4):256-8
pubmed: 10742062
Ann Intern Med. 2010 Apr 6;152(7):444-55; W144-54
pubmed: 20368650
Radiol Oncol. 2022 Aug 14;56(3):380-389
pubmed: 35848608
J Natl Cancer Inst. 2016 Mar 01;108(7):
pubmed: 26933010
JAMA. 2011 Jun 8;305(22):2311-9
pubmed: 21642683
Br J Radiol. 2018 Jun;91(1086):20170824
pubmed: 29493262
J Clin Oncol. 2014 Jul 20;32(21):2217-23
pubmed: 24752044
Radiology. 1992 Aug;184(2):421-3
pubmed: 1320281
Cancer. 2004 Feb 1;100(3):631-40
pubmed: 14745882
J Natl Cancer Inst. 2003 Jul 2;95(13):971-80
pubmed: 12837833
Rep Pract Oncol Radiother. 2014 Jul 16;19(5):317-21
pubmed: 25184056
J Clin Oncol. 2019 Jul 1;37(19):1647-1656
pubmed: 31075046
J Clin Oncol. 2011 Jun 20;29(18):2466-73
pubmed: 21576642
Ann Oncol. 2008 Jan;19(1):62-7
pubmed: 17878177

Auteurs

Lorna Zadravec Zaletel (L)

Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Maja Cesen Mazic (M)

Department of Oncology and Haematology, University Children's Hospital, University Medical Centre, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Janez Jazbec (J)

Department of Oncology and Haematology, University Children's Hospital, University Medical Centre, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Gregor Kos (G)

Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Miha Toplak (M)

Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Danijela Štrbac (D)

Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Classifications MeSH